Intellectual Property in Regenerative Bioengineering from CIRM funded research in regenerative medicine at the University of California, Santa Barbara.

Grant Award Details

Intellectual Property in Regenerative Bioengineering from CIRM funded research in regenerative medicine at the University of California, Santa Barbara.

Grant Type: Patent Assistance Fund Awards

Grant Number: PA1-07216

Investigator:

Name:	Bernadette McCafferty
Institution:	University of California, Santa Barbara
Type:	PI

Award Value: $23,564

Status: Closed

Grant Application Details

Application Title: Intellectual Property in Regenerative Bioengineering from CIRM funded research in regenerative medicine at the University of California, Santa Barbara.

Public Abstract: UCSB's Office of Technology & Industry Alliances (TIA) was established in 2005 with two primary responsibilities: manage intellectual property from UCSB research (including out-licensing) and manage the many agreements with industry partners who support research collaborations (e.g. research, material transfer, and non-disclosure agreements and memorandums of understanding). Our goal is to build effective, long-term and mutually-beneficial relationships with our industry partners for the benefit of the university and the public. Our portfolio includes over 600 active inventions, 50% of which are under active licensing arrangements.

Continued collaborative and cross-discipline development and research of stem-cell technologies is necessary. UCSB's Center for Stem Cell Biology and Engineering is perfectly positioned to develop the CIRM inventions. The center focuses on basic biological questions and engineering challenges related to stem cell research. UCSB's renowned faculty includes five winners of the Nobel Prize and scores of elected members of national and international academies and societies. UCSB has 12 National Centers and Institutes, multiple top-ten departments, and is a member of the prestigious Association of American Universities.

UCSB has the research and development resources and talent as well as a strong technology transfer group. We are qualified to create products and find business partners to develop those products and make them available to Californians.

Statement of Benefit to California:	The State of California faces immense challenges to its health care system; soaring medical costs are due in part to caring of our aging population. The percentage of elderly in California is expected to grow from 14 percent in 1990 to 22 percent in 2030. Chronic degenerative diseases (e.g. Alzheimer's , Parkinson's, age-related macular degeneration, cancer, diabetes, cardiovascular) affect a growing number of in Californians. Major innovative approaches are imperative. Human embryonic stem cells and induced pluripotent stem cells have potential to treat disease and injury because they are pluripotent in their ability to form most cell types in the body. They also have potential in screening new drug candidates, and in understanding the molecular mechanisms of human development and disease. Adult stem cells too hold promise for multiple applications. Ongoing research at UC Santa Barbara aims to harness the potential of these cells and carry out the required preclinical studies to move technology from the lab to the clinic. UC Santa Barbara has unique strengths in vision research, neurobiology and bioengineering. We collaborate in novel interdisciplinary projects and have developed some impressive inventions. This grant allows us to patent our innovations and make them attractive to industry. Californians benefit from technology that addresses a critical need in the field of stem cell research and suggest new therapies for degenerative conditions afflicting millions.